KR101236224B1 - 항 이피캠 면역글로불린 - Google Patents

항 이피캠 면역글로불린 Download PDF

Info

Publication number
KR101236224B1
KR101236224B1 KR1020067016339A KR20067016339A KR101236224B1 KR 101236224 B1 KR101236224 B1 KR 101236224B1 KR 1020067016339 A KR1020067016339 A KR 1020067016339A KR 20067016339 A KR20067016339 A KR 20067016339A KR 101236224 B1 KR101236224 B1 KR 101236224B1
Authority
KR
South Korea
Prior art keywords
cancer
epcam
administration
delete delete
immunoglobulin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020067016339A
Other languages
English (en)
Korean (ko)
Other versions
KR20070009988A (ko
Inventor
말테 페터스
메시아스 로케
나자 프랑
코넬리아 콰트
Original Assignee
암젠 리서치 (뮌헨) 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 암젠 리서치 (뮌헨) 게엠베하 filed Critical 암젠 리서치 (뮌헨) 게엠베하
Publication of KR20070009988A publication Critical patent/KR20070009988A/ko
Application granted granted Critical
Publication of KR101236224B1 publication Critical patent/KR101236224B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
KR1020067016339A 2004-02-13 2005-02-09 항 이피캠 면역글로불린 Expired - Fee Related KR101236224B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/778,915 US20050180979A1 (en) 2004-02-13 2004-02-13 Anti-EpCAM immunoglobulins
US10/778,915 2004-02-13
PCT/EP2005/001307 WO2005080428A2 (en) 2004-02-13 2005-02-09 Anti-epcam immunoglobulins

Publications (2)

Publication Number Publication Date
KR20070009988A KR20070009988A (ko) 2007-01-19
KR101236224B1 true KR101236224B1 (ko) 2013-02-22

Family

ID=34838270

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020067016339A Expired - Fee Related KR101236224B1 (ko) 2004-02-13 2005-02-09 항 이피캠 면역글로불린

Country Status (23)

Country Link
US (3) US20050180979A1 (enExample)
EP (2) EP1713830B1 (enExample)
JP (1) JP5220315B2 (enExample)
KR (1) KR101236224B1 (enExample)
CN (1) CN1976951B (enExample)
AT (1) ATE437186T1 (enExample)
AU (1) AU2005215874B2 (enExample)
BR (1) BRPI0507660A (enExample)
CA (1) CA2555694C (enExample)
DE (1) DE602005015544D1 (enExample)
DK (1) DK1713830T3 (enExample)
EA (1) EA011951B1 (enExample)
ES (1) ES2328159T3 (enExample)
IL (1) IL177069A (enExample)
MX (1) MXPA06008942A (enExample)
NO (1) NO339364B1 (enExample)
NZ (1) NZ549125A (enExample)
PL (1) PL1713830T3 (enExample)
PT (1) PT1713830E (enExample)
SI (1) SI1713830T1 (enExample)
UA (1) UA87128C2 (enExample)
WO (1) WO2005080428A2 (enExample)
ZA (1) ZA200606083B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5686493B2 (ja) 2003-01-24 2015-03-18 ユニバーシティ・オブ・ユタＵｎｉｖｅｒｓｉｔｙ Ｏｆ Ｕｔａｈ テロメアの長さを決定することによって死亡の危険性を予測する方法
AU2006268227A1 (en) 2005-07-08 2007-01-18 Xencor, Inc Optimized anti-Ep-CAM antibodies
EP1981539B1 (en) 2006-02-09 2014-07-23 Amgen Research (Munich) GmbH Treatment of metastatic breast cancer
ATE509956T1 (de) * 2006-06-08 2011-06-15 Helmholtz Zentrum Muenchen Spezifische proteaseinhibitoren und ihre verwendung in der krebstherapie
EP1865001A1 (en) * 2006-06-08 2007-12-12 Gsf-Forschungszentrum Für Umwelt Und Gesundheit, Gmbh Specific protease inhibitors and their use in cancer therapy
HRP20110620T1 (hr) 2007-04-04 2011-09-30 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. PROTUTIJELO PROTIV EpCAM I NJEGOVE UPOTREBE
CA2748265C (en) 2008-12-22 2018-04-03 University Of Utah Research Foundation Monochrome multiplex quantitative pcr
EP2480687B1 (en) * 2009-09-21 2015-01-28 Paul Walfish Methods and compositions for the diagnosis and treatment of thyroid cancer
TWI485161B (zh) * 2012-03-02 2015-05-21 Academia Sinica 抗上皮細胞黏著分子（ＥｐＣＡＭ）抗體及其使用方法
CN103387990B (zh) * 2012-09-24 2016-01-06 厦门大学 上皮细胞粘附分子的核酸适体EpCAM B及其制备方法
ES2762860T3 (es) 2013-05-22 2020-05-26 Telomere Diagnostics Inc Medidas de abundancia de telómeros cortos
CN103275226B (zh) * 2013-06-09 2017-08-29 中国科学技术大学 特异性抗人上皮细胞粘附分子（EpCAM）的单克隆抗体的制备、鉴定及应用
CN106456748A (zh) * 2014-01-08 2017-02-22 小利兰·斯坦福大学托管委员会 小细胞肺癌的靶向疗法
CA2971169A1 (en) 2014-12-30 2016-07-07 Telomere Diagnostics, Inc. Multiplex quantitative pcr
JP7073258B2 (ja) * 2015-11-19 2022-05-23 レビトープ リミテッド 望ましくない細胞の再指向性死滅に対する二成分系のための機能的抗体断片相互補完
SG11201900634VA (en) 2016-07-26 2019-02-27 Tessa Therapeutics Pte Ltd Chimeric antigen receptor
WO2020018964A1 (en) 2018-07-20 2020-01-23 Fred Hutchinson Cancer Research Center Compositions and methods for controlled expression of antigen-specific receptors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5853697A (en) * 1995-10-25 1998-12-29 The United States Of America, As Represented By The Department Of Health & Human Services Methods of treating established colitis using antibodies against IL-12
SI0970126T1 (en) * 1997-04-14 2001-08-31 Micromet Ag Novel method for the production of antihuman antigen receptors and uses thereof
US6855544B1 (en) * 1999-04-15 2005-02-15 Crucell Holland B.V. Recombinant protein production in a human cell
US7605238B2 (en) * 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
DE60239454D1 (de) * 2001-05-03 2011-04-28 Merck Patent Gmbh Rekombinanter, tumorspezifischer antikörper und dessen verwendung
US20030175268A1 (en) * 2002-01-11 2003-09-18 Saint-Remy Jean-Marie R. Method and pharmaceutical composition for preventing and/or treating systemic inflammatory response syndrome
WO2003099205A2 (en) * 2002-05-20 2003-12-04 Abgenix, Inc. Treatment of renal carcinoma using antibodies against the egfr

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Neoplasia, Vol. 5, No. 6, Pages 489-494(2003. Nov/Dec) *

Also Published As

Publication number Publication date
PT1713830E (pt) 2009-10-19
CA2555694A1 (en) 2005-09-01
AU2005215874B2 (en) 2011-01-27
EP2107071A3 (en) 2009-12-30
JP5220315B2 (ja) 2013-06-26
KR20070009988A (ko) 2007-01-19
MXPA06008942A (es) 2007-01-26
EP2107071A2 (en) 2009-10-07
ES2328159T3 (es) 2009-11-10
US20050180979A1 (en) 2005-08-18
CN1976951B (zh) 2012-03-14
DK1713830T3 (da) 2009-10-12
BRPI0507660A (pt) 2007-07-17
EP1713830B1 (en) 2009-07-22
IL177069A0 (en) 2006-12-10
NZ549125A (en) 2008-09-26
ZA200606083B (en) 2007-10-31
EA011951B1 (ru) 2009-06-30
NO20064136L (no) 2006-11-07
DE602005015544D1 (de) 2009-09-03
CN1976951A (zh) 2007-06-06
ATE437186T1 (de) 2009-08-15
AU2005215874A1 (en) 2005-09-01
UA87128C2 (ru) 2009-06-25
HK1096103A1 (en) 2007-05-25
CA2555694C (en) 2013-04-16
SI1713830T1 (sl) 2009-10-31
EP1713830A2 (en) 2006-10-25
WO2005080428A3 (en) 2005-11-10
US20120294873A1 (en) 2012-11-22
JP2008500277A (ja) 2008-01-10
NO339364B1 (no) 2016-12-05
US20070274982A1 (en) 2007-11-29
PL1713830T3 (pl) 2010-01-29
EA200601386A1 (ru) 2007-06-29
IL177069A (en) 2010-11-30
WO2005080428A2 (en) 2005-09-01

Similar Documents

Publication Publication Date Title
US20120294873A1 (en) ANTI-EpCAM IMMUNOGLOBULINS
RU2650869C2 (ru) Антитела к родственной раково-эмбриональному антигену молекуле клеточной адгезии (сеасам)
JP2022174167A (ja) Ｒｏｒ１癌の治療および転移の阻害に使用するための抗体およびワクチン
US8802826B2 (en) Anti-clusterin antibodies and antigen binding fragments and their use to reduce tumor volume
WO1994022478A1 (en) PREVENTION OF TUMORS WITH MONOCLONAL ANTIBODIES AGAINST $i(NEU)
KR20140020922A (ko) 종양 개시 세포를 인지하는 항체와 항원 및 이의 용도
JP2024026138A (ja) プラチナベースの薬剤と抗組織因子抗体－薬物コンジュゲートの組み合わせを用いるがんの治療方法
US6733752B1 (en) Prevention of tumors with monoclonal antibodies against neu
WO2019217455A1 (en) Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate
JP2025060639A (ja) Ｐｄ－１／ｐｄ－ｌ１シグナル伝達阻害剤に不応答性のがんの処置方法および医薬
CN117750980A (zh) Her2靶向抗体-药物偶联物用于治疗her2低表达乳腺癌的用途
JP2022502411A (ja) 非小細胞肺がんの処置のためのａｘｌ特異的抗体
ITRM20090081A1 (it) Uso di inibitori della proteina 90k per la preparazione di un medicamento per la cura o prevenzione dei tumori.
AU2019337248A1 (en) Medicinal composition containing monoclonal antibody or antibody fab fragment thereof, and use thereof
HK1096103B (en) Anti-epcam immunoglobulins
TW202432585A (zh) 癌症新輔助治療的組合物及方法
Garrett Peptide-based B-cell epitope vaccines targeting HER-2/neu
KR20240038204A (ko) Pd-1에 특이적으로 결합하는 항체를 유효성분으로 포함하는 신경내분비 신생물의 예방 또는 치료용 약학 조성물
KR20220002098A (ko) Lgals3bp에 특이적으로 결합하는 항체 및 이의 용도
CN115607662A (zh) 抗pd-1抗体在治疗腺泡状软组织肉瘤中的应用
HK40005045B (zh) 用於治疗ror1癌症并抑制转移的抗体和疫苗

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20160119

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20170119

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

FPAY Annual fee payment

Payment date: 20180118

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20190219

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20190219